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The potential of vaccine-elicited anti-HIV envelope antibodies to control HIV-infection was evaluated by immunizing macaques with the
HIVenvelope protein and transiently depleting them of their CD8+ cells before intravenous challenge with the pathogenic CCR5-tropic SIV/
HIV chimeric virus, SHIVSF162P4. Although sterilizing immunity was not achieved, all vaccinated animals effectively controlled infection
and remained free of disease for the duration of observation (over 3 years). In contrast, during the same period, the control animals progressed
to disease. Both the vaccinees and the controls developed robust cell-mediated antiviral and neutralizing antibody responses following
infection. A comparative analysis of these responses suggests that the more effective long-term control of infection by the vaccinated animals
is due to the more rapid development of anti-HIV envelope antibodies. These studies suggest that priming by vaccination of B cell anti-HIV
envelope responses maybe crucial for the long-term control of HIV infection.
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when a significant reduction in plasma viremia is recordedIntroduction
Vaccination methodologies that primarily elicit cell-me-
diated anti-HIV/SIV responses and no measurable neutral-
izing antibodies offer partial protection to macaques
challenged with the dual-tropic (CCR5/CXCR4), highly
pathogenic SHIV89.6P virus (Amara et al., 2001; Barouch
et al., 2000; Shiver et al., 2002). The benefit offered by the
responses elicited by such vaccination methodologies is
especially evident during the chronic phase of infection,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.12.003
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31st Street, Suite 125 Santa Monica, CA 90405, USA.in the vaccinated, as compared to unvaccinated, animals.
Importantly, most vaccinated animals are protected from the
rapid depletion of their CD4+ T cells and the rapid progres-
sion to disease, hallmarks of SHIV89.6P-infection (Reim-
ann et al., 1996), even though the emergence of escape
mutants has been documented in one of these animals,
which eventually developed AIDS (Barouch et al., 2002,
2003). Interestingly, however, vaccine-elicited cell-mediated
antiviral responses fail to control infection of macaques by
SIVmac239, a CCR5-tropic virus (Horton et al., 2002). The
exact reason(s) for the difference in protection against
SHIV89.6P and SIVmac239 are not yet understood, but
the absence of strong neutralizing antibodies during vacci-
nation and following challenge was suggested to be respon-
sible for the recorded lack of protection during SIVmac239
challenge (Horton et al., 2002).
Table 1
Immunization schedule, treatment, and viral challenge
Animal Immunizationa Vaccineb CD8
depletionc
Challenged Referencee
K863 4  DNA/1Pr DV2C OKT8F SHIVSF162P4
I708 4  DNA/1Pr DV2C OKT8F SHIVSF162P4
N472 4  DNA/1Pr SF162C OKT8F SHIVSF162P4
P655 4  DNA/1Pr SF162C OKT8F SHIVSF162P4
M844 OKT3 SHIVSF162P4
C640 OKT3 SHIVSF162P4
J408 4  DNA/2Pr DV2F OKT8F SHIVSF162P4 Cherpelis et al.
H445 4  DNA/2Pr DV2F OKT8F SHIVSF162P4 Cherpelis et al.
AT54 SHIVSF162P4 Cherpelis et al.
A141 SHIVSF162P4 Cherpelis et al.
a The animals were immunized (both intramuscularly and intradermally) 3
times with a DNA vector expressing the HIV Env. A fourth DNA
immunization was administered 10 months later and at the same time the
animals were immunized with the purified soluble trimeric HIV envelope
recombinant protein. Animals J408 and H445 received a second
immunization with recombinant protein (in the absence of DNA
immunization) 2 months following the first protein administration.
b The vaccine was the gp140 envelope form derived from the SF162DV2
virus (DV2) or derived from the SF162 virus (SF162). C: The gp120–gp41
cleavage site is present on the immunogen during the DNA phase of
immunization. F: The gp120–gp41 cleavage site is absent on the
immunogen during the DNA phase of immunization.
c Transient depletion of CD8+ cells from the immunized animals was
achieved by administering the anti-CD8 MAb OKT8F. Two control
animals, M844 and C640, received OKT3, a nonspecific isotype control
MAb.
d The animals were challenged intravenously 7 weeks following the last
protein-boost immunization.
e We previously reported on the immunization and challenge as well on the
viral load data during the acute phase of infection of these four animals and
are now reporting on the virological and immunological analyses performed
during chronic infection.
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neutralizing antibodies, during the chronic phase of infec-
tion appears to be necessary for the effective control of viral
replication in macaques infected with SIV and SHIV, in-
cluding SIVmac239 (Johnson et al., 2003; Schmitz et al.,
2003) and SHIV89.6P (Amara et al., 2002a; Lu et al., 1998;
Rasmussen et al., 2002). However, the protective role of
neutralizing antibodies during primary SIV, HIV, or SHIV-
infection is less well defined. A strong indication of the
beneficial role that vaccine-elicited neutralizing antibodies
could have during acute infection is provided from passive
antibody-infusion studies. The administration of potent
neutralizing antibodies to macaques before their exposure
to SIV or SHIV, or to chimpanzees before their exposure to
HIV, can result in sterilizing immunity when the titers of the
infused antibodies are significantly high at the time of
challenge (Baba et al., 2000; Conley et al., 1996; Emini et
al., 1992; Hofmann-Lehmann et al., 2001; Igarashi et al.,
1999; Mascola et al., 1999, 2000; Nishimura et al., 2002;
Parren et al., 2001; Shibata et al., 1999; Ward et al., 1991).
These results suggest that vaccine-elicited neutralizing anti-
bodies could play an important role in controlling early viral
replication in a newly infected host and that a vaccine
against HIV should elicit not only cell-mediated antiviral
responses, but also neutralizing antibodies. Whether the
various vaccination methodologies that are currently being
evaluated in primates and humans will be able to elicit and
sustain for extended periods of time, neutralizing antibodies
at titers capable of offering sterilizing immunity is un-
known. It is also not well established whether vaccine-
elicited neutralizing antibodies at titers that are suboptimal
for sterilizing immunity would offer any benefit to the
vaccinee. Finally, it is unknown whether the presence of
memory B cells with anti-HIV envelope specificity will be
beneficial to a vaccinated but eventually infected host.
In an attempt to address the above issues, we immu-
nized rhesus macaques with the envelope proteins derived
from the SF162 and SF162DV2 HIV-1 isolates (Stamatatos
and Cheng-Mayer, 1998) using the ‘‘DNA-prime plus
protein-boost’’ vaccination methodology. To examine the
protective role of the neutralizing antibodies elicited during
vaccination, we artificially depleted the CD8+ cells from
the vaccinated animals before their exposure to virus. The
virus we used as a challenge was SHIVSF162P4 whose
envelope utilizes the CD4 antigen and the CCR5 chemo-
kine receptor to mediate virus–cell fusion (Harouse et al.,
1999). Thus, unlike SHIV89.6P, whose envelope primarily
utilizes the CXCR4 receptor for entry into primary cells
(Zhang et al., 2000), SHIVSF162P4 has a similar coreceptor
utilization profile to that of the vast majority of HIV-1
isolates that establish infection in humans (Bjorndal et al.,
1997; Connor et al., 1997; Hu et al., 2000; Liu et al., 1996;
Long et al., 2002; Michael et al., 1997; Samson et al.,
1996; Scarlatti et al., 1997).
Our results strongly suggest that priming by vaccination
of B cell responses against the HIV envelope, includingneutralizing antibodies, is crucial for the effective long-term
control of viral replication in a vaccinee, if HIV-infection
takes place.Results
Comparison of the SF162gp140 andDV2gp140 immunogens
in eliciting neutralizing antibodies and cell-mediated
responses against SHIVSF162P4
Macaques immunized with soluble oligomeric HIV en-
velope glycoproteins (gp140) derived from the HIV-1
SF162 and SF162DV2 viruses, termed SF162gp140 or
DV2gp140, respectively, develop neutralizing antibodies
against the homologous HIV-1 SF162 virus and certain
heterologous primary HIV-1 isolates (Barnett et al., 2001).
The envelope glycoprotein of the SF162DV2 virus is
derived from that of the SF162 virus by artificially deleting
30 out of the 40 amino acids of the second hypervariable
region (Stamatatos and Cheng-Mayer, 1998). This modifi-
cation alters the immunogenic properties of the SF162gp140
protein (Srivastava et al., 2003). As a result, the
DV2gp140 immunogen appears to be more effective than
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cross-reactive neutralizing antibodies (Barnett et al., 2001;
Srivastava et al., 2003).
We previously reported that two rhesus macaques (H445
and J408) immunized with DV2gp140 developed antibodies
that reduced plasma viral load levels during the acute phase
of infection by the R5-tropic, highly replication-competent
SHIVSF162P4 virus (Cherpelis et al., 2001b). In the studies
presented here, we compared the ability of the antibodies
elicited the SF162gp140 and DV2gp140 immunogens to
protect from SHIVSF162P4 infection. To this end, we immu-
nized macaques with the SF162gp140 (N473 and P655
animals) or the DV2gp140 (I708 and K863 animals) pro-
teins using the ‘‘DNA-prime plus protein-boost’’ immuni-
zation methodology. A summary of the immunization
protocol and animal treatment of our previous and current
studies is presented in Table 1. We note that in the current
study, the DV2gp140 immunogen expressed during the
DNA phase of immunization lacked the gp120–gp41 cleav-
age site, although in the previous study, this cleavage site
was present.
Potent binding antibody responses were evident in all
four animals following the ‘‘booster’’ immunization withFig. 1. Development of anti-HIV envelope responses during ‘‘DNA-prime plus pro
(A) Generation of binding antibodies against the soluble oligomeric gp140 HIV
following a fourth DNA administration in combination with the purified recom
antibodies at the day of challenge against the challenge SHIVSF162P4 virus. Horiz
Nonspecific neutralization was corrected as discussed in the Materials and method
envelope immunogen and animals I708 (n) and K863 (x) with the related DV2gp1
months following the last DNA immunization using the IFN-g ELISPOT assay.the soluble oligomeric gp140 envelope proteins (Fig. 1A).
However, the titer of binding antibodies did not always
correlate with the titer of neutralizing antibodies against the
challenge virus, SHIVSF162P4 (Fig. 1B). Thus, animal N472
had stronger neutralizing antibody responses than animals
P655 or K863. No significant difference in the ability of the
SF162gp140 and DV2gp140 proteins to elicit anti-
SHIVSF162P4 neutralizing antibodies was recorded during
the present studies.
At the end of the DNA-immunization protocol, anti-HIV
envelope cell-mediated responses were measurable in three
(P655, N472, and I708) out of the four vaccinated animals
(Fig. 1C). These responses were weak, but this is not
unexpected, because intramuscular or intradermal DNA
administration does not elicit the generation of potent
cellular-mediated antiviral responses, and additional immu-
nizations with viral vectors (such as MVA) are required to
boost such responses before viral challenge (Amara et al.,
2001, 2002a, 2002b; Horton et al., 2002; Shiver et al.,
2002). The anti-HIV cellular-mediated responses elicited
during the DNA phase of immunization were not ‘‘boosted’’
following the administration of the recombinant envelope
gp140 protein (data not shown).tein-boost’’ vaccination with the SF162gp140 and DV2gp140 immunogens.
envelope proteins during three DNA administrations (black arrows) and
binant gp140 proteins (white arrow); (B) Neutralizing potency of serum
ontal dotted lines indicate the 90%, 70%, and 50% levels of neutralization.
s. Animals P655 (5) and N472 (o) were immunized with the SF162gp140
40 envelope. (C) Cellular-mediated anti-HIVenvelope responses recorded 6
ology 320 (2004) 167–180Transient depletion of CD8+ cells before viral challenge
To better appreciate the benefits offered by the
SF162gp140- or the DV2gp140-elicited anti-HIV envelope
antibodies during the early stages of infection, and to
eliminate any potential involvement of CD8+ cells with
antiviral activity during this period, we depleted before
viral challenge the CD8+ cells from the vaccinated ani-
mals. CD8+ cell depletion was achieved as we previously
reported (Cherpelis et al., 2001b), by administrating the
anti-CD8 MAb OKT8F (Fig. 2). An isotype control MAb,
OKT3 (which does not recognize the macaque CD3
antigen) was administered to the control animals (M844
and C640). It was previously demonstrated that adminis-
tration of anti-CD8 MAbs to macaques does not affect the
timing of peak plasma viremia and the peak plasma
viremia levels during challenged with SIV (Schmitz et
C. Buckner et al. / Vir170Fig. 2. Transient depletion of CD8+ cells from the blood before viral challenge. T
infused with the anti-CD8 MAb OKT8F, while the control animals M844 (E) and C
recognize the macaque CD3 antigen. Arrows indicate the time of MAb-infusion
lymphocytes; ., CD4+ T lymphocytes; *, CD3+ T lymphocytes.al., 1999a). OKT8F administration resulted in the complete
but transient depletion of CD8+ cells from the periphery,
which lasted between 9 (animal P655, Fig. 2D) and 14
days (animal K863, Fig. 2B). The CD8+ cells were also
eliminated from the peripheral lymph nodes examined
(over 99% loss at 4 days following the last OKT8F
infusion). OKT3 administration had no detectable effect
on the CD4/CD8 T cell ratio in the lymph nodes of the
control animals (C640 and M844). Concomitant with the
loss of CD8+ cells from the periphery, a loss of cell-
mediated anti-HIV envelope responses was recorded (see
below). CD8+ T lymphocytes gradually reemerged in the
periphery (Fig. 2), as well as in the lymph nodes tested
(axillary and inguinal) of the vaccinated animals (by day
28 post challenge, the CD4+/CD8+ T cell ratio in the
lymph nodes tested was similar to that recorded before
OKT8F administration).he vaccinated animals I708 (A), K863 (B), N472 (C), and P655 (D) were
640 (F) were infused with the isotype control MAb OKT3, which does not
and dotted lines indicate the time of SHIVSF162P4 challenge. w , CD8+ T
ology 320 (2004) 167–180 171Titers of vaccine-elicited neutralizing antibodies against the
challenge virus and acute plasma viremia levels
The titers of vaccine-elicited neutralizing antibodies
against the challenge virus were not sufficient to offer
sterilizing immunity, and as a result, both the vaccinated
and the control animals became infected upon their intrave-
nous exposure to SHIVSF162P4 (Fig. 3A). Peak levels of
plasma viremia were recorded 12–15 days post-challenge.
The mean peak viremia in the vaccinated animals was
1794292 RNA copies per milliliter and in the controls
9750000 RNA copies per milliliter. Due to the small
number of animals in the two groups, this difference is
not statistically significant. However, the vaccinated animal
N472 with the strongest neutralizing antibody response
against SHIVSF162P4 at the day of challenge had the lowest
peak viremia level during acute infection (7180 RNA copies
per milliliter) (Fig. 3B).
C. Buckner et al. / Vir    
    
Fig. 3. Protective role of vaccine-elicited neutralizing antibodies during
acute SHIVSF162P4 infection. (A) Plasma viral load levels in controls: M844
(+) and C640 (*) (dotted lines); and vaccinated animals: P655 (5), N472
(o), I708 (n), and K863 (x) (solid lines). The limit of detection was 500
RNA copies per milliliter of plasma for the first 584 days post-challenge
and subsequently 125 RNA copies per milliliter. (y) Indicates the time of
death of the two control animals. (B) Peak plasma viremia levels recorded
in the vaccinated and control animals (black bars) and the anti-SHIVSF162P4
neutralizing potency of sera at the day of viral challenge (white bars).
Fig. 4. Development of anti-HIV binding and anti-SHIVSF162P4 neutralizing
antibodies following infection. The end point ELISA titers of antibodies
that recognize the HIV envelope (A) and the development of anti
SHIVSF162P4 neutralizing antibody responses (B) following infection were
determined longitudinally as described in the Materials and methods.
Control animals: M844 (+) and C640 (*) (dotted lines); and vaccinated
animals: P655 (5), N472 (o), I708 (n), and K863 (x) (solid lines).Development of anamnestic and de novo antiviral responses
following SHIVSF162P4 infection in vaccinated and control
animals
All vaccinated animals developed potent anamnestic
binding anti-HIV envelope antibody responses during the
first 2 weeks post-challenge (Fig. 4A). The vaccinated
animals with the lower neutralizing antibody titers on the
day of challenge (animals I708, K863, and P655) developed
stronger anamnestic anti-HIV envelope binding-antibody
responses than the vaccinated animal with the strongest
neutralizing antibody responses on the day of challenge
(animal N472). This indicates that the extent of virus
replication (i.e., amount of envelope antigen produced
during infection and presented to the immune system)
determines the potency of the elicited anamnestic anti-
envelope responses. The titers of neutralizing antibodies
also increased in all vaccinated animals (Fig. 4B), but with
slower kinetics to those of binding anti-HIV envelope anti-
Fig. 6. CD4+ T lymphocytes in the blood of SHIVSF162P4-infected
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anamnestic anti-HIV envelope antibody responses coincided
with the recorded initial decrease in plasma viremia during
acute infection (Fig. 3A). The control animals (M844 and
C640) also developed binding and neutralizing antibodies
against SHIVSF162P4. However, the emergence of such
antibodies was delayed by 3–4 weeks as compared to the
vaccinated animals.
Interestingly, even though CD8+ lymphocytes reap-
peared in the periphery of most vaccinated animals within
the fist 21 days post-challenge (Fig. 2), HIV envelope-
specific cell-mediated responses did not become detectable
until later (Fig. 5). This suggests that CD8+ cell depletion
resulted in the elimination of most (or all) memory HIV
envelope-specific CD8+ cells elicited during vaccinationFig. 5. Emergence of cellular-mediated antiviral responses during
SHIVSF162P4 infection. Cellular-mediated anti-SIV Gag (A) and anti-HIV
Env (B) cellular-mediated responses, as well as SEB-mediated (0.5 Ag per
ml) cellular responses (C), were determined by IFN-g ELISPOT using
cryopreserved PBMC collected at the indicated times following SHIVSF162P4
infection from the controls (C640n and M8445) and vaccinated (I708m,
N472 n, P655 5, and K863 l) animals. Anti-Env responses were not
evaluated for animal C640 at days 70 and 102 post-infection, and for animal
M844 at day 21 post-infection. Anti-Gag responses were not evaluated for
animals C640, N472, and K863 at day 70 post-infection and animal M844 at
day 21 post-infection. SEB-mediated responses were not evaluated for
animal C640 at days2, 0, 70, and 102 post-infection and for animalM844 at
day 21 post-infection.
macaques. The numbers of CD4+ T lymphocytes in the periphery were
monitored longitudinally following the intravenous exposure of macaques
to SHIVSF162P4. Control animals: M844 (+) and C640 (*) (dotted lines); and
vaccinated animals: P655 (5), N472 (o), I708 (n), and K863 (x) (solid
lines). (y) Indicates the time of death of the two control animals.(Fig. 1C). De novo anti-SIV Gag responses (Fig. 5A) were
generated in all animals following infection and were in
general more potent and more consistently recorded than the
anti-HIV Env responses (Fig. 5B) in all animals. PBMC
from all animals was similarly susceptible to PHA-mediated
stimulation throughout the course of infection (Fig. 5C). No
difference in the rate at which cellular antiviral responses
emerged in the periphery of the vaccinated and control
animals was evident (Fig. 5). Therefore, we believe that
the more rapid elimination a virus from the periphery of the
vaccinated animals, as compared to the controls, during
acute infection (Fig. 3) is not due to the effect of CD8+ cell-
mediated antiviral responses. However, we expect that if the
CD8+ cells were not artificially depleted from the vaccinat-
ed animals before viral challenge, vaccine-elicited cell-
mediated anti-HIV envelope responses would have also
contributed to an earlier viral clearance in these animals,
as compared to controls.
Long-term control of SHIVSF162P4 infection
We have monitored this group of SHIVSF162P4-infected
animals for over 2 years. All the vaccinated animals have
stable CD4+ T cell numbers (Fig. 6) and, with the exception
of animal P655 (which was immunized with the
SF162gp140 immunogen and was the animal with the
weakest vaccine-elicited neutralizing antibody responses,
Fig. 1B), they remain plasma RNA-negative (Fig. 3A).
Animal P655 has remained viremic throughout the period
of observation, but with decreasing levels of plasma vire-
mia. The control animal C640 remained plasma RNA-
positive for the duration of observations (approximately
105 RNA copies per ml of plasma during chronic infection),
with decreasing CD4+ T cells in the periphery (Fig. 6) and
died of AIDS (643 days post-infection), although it devel-
oped both binding and neutralizing antibodies (Figs. 4A and
C. Buckner et al. / Virology 320 (2004) 167–180 173B, respectively) as well as potent cellular antiviral responses
(Fig. 5). At necropsy, although CD8+ T lymphocytes were
present in the spleen and thymus, and in the colonic,
mesenteric, inguinal, iliac, and axillary lymph nodes of
animal C640, CD4+ lymphocytes were absent from these
sites. The control animal M844 remained plasma RNA-
negative and with stable CD4+ T lymphocyte numbers
during the first 754 days of SHIVSF162P4 infection, even
though during the acute phase of infection, this animal had
similarly high plasma viremia as animal C640 (Fig. 3). Such
differences in viral load levels during chronic infection
among nonimmunized macaques infected with SIVor SHIV
are well documented (Marthas et al., 2001; Parker et al.,
2001; Reimann et al., 1994; Watson et al., 1997). Subse-
quently, however, this animal experienced loss of peripheral
CD4+ T lymphocytes (Fig. 6), severe weight loss, devel-
oped pneumonia, and was euthanized at day 888 post-
infection. At necropsy, CD4+ T lymphocytes were absent
from all lymph nodes tested (axillary, inguinal, mesenteric,
and iliac). Although we did not record differences in the
quality of the antibody or cell-mediated antiviral responses
between this and the other animals, we note that PBMCFig. 7. Long-term suppression of SHIVSF162P4 replication in previously vaccinated
milliliter, horizontal dotted line); (B) CD4+ T lymphocyte numbers in blood; (C) C
envelope antibody responses in SHIVSF162P4-infected macaques. Controls (A141,.
solid lines). (y) Indicates the time of death of the two control animals.from animal M844 lost their ability to secrete IFN-g upon
stimulation with envelope or gag-derived peptides toward
the later stages of infection (Figs. 5A, B).
Involvement of cell-mediated and neutralizing responses in
the long-term control of SHIVSF162P4 infection
When CD8+ cells are artificially depleted from maca-
ques chronically infected with SHIV or SIV, a rapid rise in
plasma viremia is recorded (Jin et al., 1999; Matano et al.,
1998; Rasmussen et al., 2002; Schmitz et al., 1999a). This
observation suggests that CD8+ cell-mediated antiviral
responses are involved in controlling SHIV and SIV infec-
tion of macaques, as in HIV-infected humans (Koup et al.,
1994), although the protective role of neutralizing anti-
bodies was also reported in cases of macaques chronically
infected with X4-tropic SHIVs (Rasmussen et al., 2002).
We wanted to examine to what extent cell-mediated anti-
viral responses are involved in the control of chronic
infection by an R5-tropic SHIV, in a setting where strong
neutralizing antibody responses were present during chronic
infection (Fig. 4).macaques. (A) Plasma viral load (limit of detection is 500 RNA copies per
D8+ T lymphocyte numbers in blood; and (D) evolution of binding anti-HIV
, and AT54, x, dotted lines) and vaccinated animals (J408, w , and H445,5,
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H445) immunized with DV2gp140, artificially depleted of
their CD8+ cells and challenged with SHIVSF162P4, had
controlled infection during acute infection (Cherpelis et al.,
2001a, 2001b). The immunization and treatment schedule of
these animals was previously reported (Cherpelis et al.,
2001a, 2001b) and is summarized here in Table 1. We
now have monitored these animals for over 3 years. They
have no detectable virus in the periphery (Fig. 7A), stable
CD4+ T and CD8+ T lymphocytes (Figs. 7B and C,
respectively), stable anti-HIV envelope antibody titers
(Fig. 7D), no signs of emergence of escape mutants, and
no signs of disease development for the entire period of
observation.
By contrast, the two control animals of this group (AT54
and A141) had sustained viremia throughout the entire
period of observation. One of them (AT54) had very high
plasma viral load levels during and following acute infec-
tion (Fig. 7A); decreasing numbers of CD4+ T lymphocytes
(Fig. 7B), and died from AIDS within 16 weeks of chal-
lenge (Cherpelis et al., 2001b). The second control animal
(A141) had high levels of plasma viremia during acuteFig. 8. Role of cellular-mediated and antibody responses in the long-term control o
mediated responses during chronic infection were determined by IFN-g ELISPOT
challenge. Numbers in parentheses indicate the time of PBMC collection in respect
0.5 Ag/ml SEB (5) are also shown. (B) Depletion of CD8+ cells from the blood; (C
is the limit of detection); (D) changes in CD4+ cell numbers in the blood; and (E) in
MAb, cM-T807 in the vaccinated animals H445 (5) and J408 (w). The arrow ininfection and remained viremic during chronic infection
(Fig. 7A), with stable CD4+ and CD8+ T cell numbers in
the blood for the first 500 days following infection (Figs. 7B
and C, respectively). Subsequently, both CD4+ and CD8+ T
cell numbers decreased. During the entire period of obser-
vation, the anti-HIV envelope binding antibody titers grad-
ually increased in the animal, as a consequence of the
continuous viral replication (Fig. 7D). This animal was
euthanized at day 670 post-challenge because of severe
health complications due to endometriosis. However, at
necropsy, this animal had appreciable viremia in the spleen
(143000 RNA copies per milligram of tissue), inguinal
(38450 RNA copies per milligram of tissue), axillary
(16000 RNA copies per milligram of tissue), and mesenteric
(722 RNA copies per milligram of tissue) lymph nodes. In
addition, although CD8+ T lymphocytes were present in all
these tissues at necropsy, CD4+ T lymphocytes were unde-
tectable (data not shown). Therefore, we believe that this
control animal was progressing to AIDS at the time it was
euthanized.
As shown in Fig. 8A, cellular-mediated responses, both
against the HIV Env and the SIV Gag proteins, weref SHIVSF162P4 infection. (A) Anti-HIV Env ( ) or the SIV Gag (n) cellular-
using cryopreserved PBMC collected at the indicated days following viral
to administration of the anti-CD8 MAb cM-T807. Responses obtained with
) increase in plasma viremia (500 viral RNA copies per milliliter of plasma
crease in anti-HIVenvelope antibodies upon administration of the anti-CD8
(B) to (E) indicates the time of cM-T807 administration.
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the chronic phase of infection. The human/mouse chimeric
anti-CD8 MAb cM-T807 (Schmitz et al., 1999a, 1999b)
was administered to these two animals 886 days post-
challenge. The CD8+ cells were thus artificially depleted
for 7 days in animal H445 and 14 days in animal J408 (Fig.
2B). The observed duration of CD8+ cell depletion is
shorter than what is usually achieved with this anti-CD8
MAb (Schmitz et al., 1999a, 1999b), most likely because
these two animals had been infused with the mouse anti-
CD8 MAb, OKT8F, before viral challenge (as discussed
above and Cherpelis et al., 2001b) and had therefore been
sensitized to mouse IgG. Concomitant with the recorded
reduction in CD8+ cell numbers in the periphery, a reduc-
tion in cell-mediated antiviral activity (both anti-HIV Env
and anti-SIV Gag) was recorded (Fig. 8A). In parallel with
this loss of cell-mediated antiviral activity, a limited burst in
plasma viremia (Fig. 8C) was recorded in both animals
(13084 and 115475 RNA copies per milliliter of plasma in
animal H445 and J408, respectively). The fact that weak
SIV Gag-specific cellular responses were still recorded in
PBMC collected at the time of CD8+ cell depletion (for
example, at 3 days of post-cM-T807 administration, Fig.
8B) in both animals probably indicates that a fraction of the
CD4+ cells (whose numbers were minimally affected
during CD8+ cell depletion, Fig. 8D) have an antiviral
activity in these animals. Once the CD8+ T cells reappeared
in the periphery, an increase in cellular-mediated antiviral
activity was evident (Fig. 8B) and a concomitant reduction
in plasma viremia to undetectable levels was once again
recorded in both animals (Fig. 8C). In parallel, however, to
the increase in plasma viremia upon CD8+ cell depletion, a
rapid increase in the anti-HIV envelope antibody titers was
recorded in these animals (Fig. 8E).
The above observations suggest therefore that both cell-
mediated responses and anti-HIV envelope antibodies most
likely participate in the effective long-term control of
chronic infection in these two previously vaccinated but
chronically infected SHIVSF162P4 animals. They also indi-
cate that the CD4+ helper and B cells remain functional for
extended periods of time in animals that are capable of
controlling infection by R5-tropic SHIVs.Discussion
The ultimate goal of a vaccine against HIV is to prevent
infection. To this end, an effective vaccine must elicit the
generation of very high titers of neutralizing antibodies
(Nishimura et al., 2002; Parren et al., 2001). However,
although sterilizing immunity against highly replication-
competent SHIV viruses has been shown to occur in the
case of prophylactic neutralizing antibody-infusion studies
(Baba et al., 2000; Hofmann-Lehmann et al., 2001; Mascola
et al., 1999, 2000; Parren et al., 2001; Shibata et al., 1999),
this level of protection is not currently achievable byvaccination. In the current studies, we aimed at examining
the protective role of vaccine-elicited neutralizing antibodies
both during the acute and chronic phases of infection. We
also wanted to determine whether a vaccinated but ulti-
mately infected individual will be more effective in con-
trolling viral replication, in the absence of anti-retroviral
treatment, than in infected but previously unvaccinated
individual.
Our current challenge studies were conducted with the
highly replication-competent SHIVSF162P4 virus. This virus
was chosen because it is R5-tropic, like the majority of HIV
isolates responsible for establishing infection in humans
(Bjorndal et al., 1997; Connor et al., 1997; Hu et al.,
2000; Liu et al., 1996; Long et al., 2002; Michael et al.,
1997; Samson et al., 1996; Scarlatti et al., 1997). In contrast
to the other pathogenic SHIVs, such as SHIV89.6P, which
induce an unusually rapid depletion of CD4+ T lympho-
cytes and a very rapid progression to disease (Cayabyab et
al., 1999; Luciw et al., 1999; Reimann et al., 1996),
SHIVSF162P4 induces a gradual, but irreversible, loss of
CD4+ T lymphocytes from the periphery and the lymph
nodes, similar to what is observed in most cases of humans
infected by HIV.
The amino acid composition of the envelope of
SHIVSF162P4 is closely related, but not identical, to the
SF162gp140 and DV2gp140 envelope immunogens used
here (McCaffrey and Stamatatos, unpublished data). Re-
gardless, we consider the SHIVSF162P4 challenge to be a
‘‘homologous’’ challenge. We are in the process of evalu-
ating and comparing the protective potential of antibodies
elicited by these two immunogens, during ‘‘heterologous’’
viral challenge. However, our studies allowed us to examine
the role of anti-HIV envelope binding, in general, and
neutralizing antibodies, more specifically, that are elicited
by the ‘‘DNA-prime plus recombinant protein-boost’’ vac-
cination methodology, in controlling the replication of an
R5-tropic virus during the acute and chronic phases of
infection.
The neutralizing antibody titers elicited in our animals
following a single ‘‘protein-boost’’ immunization with the
SF162gp140 and DV2gp140 immunogens were insuffi-
cient to offer sterilizing immunity against intravenous
SHIVSF162P4 challenge. In the future, it would be important
to examine whether additional immunizations with these
recombinant envelope proteins will enhance the titers of
neutralizing antibodies to levels that will prevent infection.
Regarding the immunogenic properties of these two pro-
teins in nonhuman primates, we recently reported that
elimination of the V2 loop from the SF162gp140 immuno-
gen alters the immunogenicity of several gp120 domains,
especially that of the V1 and V3 loops (Srivastava et al.,
2003). Despite the difference in the type of antibodies
elicited by these two immunogens, we did not record
differences in the ability of the SF162gp140- and
DV2gp140-immunized animals to control SHIVSF162P4 in-
fection during acute infection. Clearly, additional studies
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determine whether the antibodies elicited by these two
immunogens are equally effective in protecting from
homologous viral challenge. The current results were
not, however, totally unexpected because although the
DV2gp140 immunogen elicits in macaques higher anti-
HIV-1SF162 neutralizing antibodies than the SF162gp140
immunogen (Barnett et al., 2001; Srivastava et al., 2003),
the neutralizing antibody titers are not different enough to
result in significant differences in reduction of acute
viremia, as numerous studies conducted with passively
administered neutralizing antibodies have indicated (Nish-
imura et al., 2002; Parren et al., 2001). In addition, in the
present study, the DV2gp140 immunogen expressed during
the DNA phase of immunization lacked the gp120–gp41
cleavage site. In our previous study, the DV2gp140 immu-
nogen contained the gp120–gp41 cleavage site (Cherpelis et
al., 2001b). The absence of this cleavage site alters the
antigenic (Stamatatos et al., 2000) and immunogenic prop-
erties of the DV2gp140 protein, including its ability to elicit
neutralizing antibodies (Srivastava et al., 2003). It is not yet
known whether immunization with the DV2gp140 protein
expressing an intact gp120–gp41 cleavage site will result in
the generation of higher titers of protective antibodies, as
compared to immunization with the SF162gp140 protein.
The current studies were exploratory in nature and
conducted with a few animals. However, the fact that in
this study, and our previous one (Cherpelis et al., 2001b),
the vaccinated animals with the highest serum neutralizing
activity at the day of challenge had the lowest levels of
plasma viremia during acute infection, suggests that vac-
cine-elicited neutralizing antibodies contribute to the control
of viral replication, early upon infection.
Irrespective of the extent to which infection was con-
trolled during acute infection, all vaccinated animals rapidly
developed anamnestic binding anti-HIV envelope and neu-
tralizing antibodies against the challenge virus. The emer-
gence of these responses coincided with the recorded rapid
reduction in plasma viremia levels during acute infection,
when anti-envelope and anti-gag cell-mediated responses
were undetectable in the periphery. At this stage of the
infection (and also during the chronic phase of infection),
apparently anti-SHIVSF162P4 envelope antibodies could have
also participated in the elimination of virions from the
periphery through mechanisms other than direct prevention
of cell infection (neutralization) (Amara et al., 2002a;
Burton, 2002).
The fact that detectable cellular antiviral responses
emerged at the same rate in the vaccinated and control
animals (due to the artificial CD8+ cell depletion in the
former animals), although the emergence of anti-HIV enve-
lope binding and neutralizing antibodies was delayed in the
latter animals, suggests that the more effective ability of the
vaccinated animals to control viral replication during the
chronic phase of infection is related to their ability to mount
a more rapid anti-HIV envelope antibody response duringacute infection. It is possible that the presence of such
responses at the day of challenge and the subsequent
rapid ‘‘boosting’’ of these responses in the vaccinated
animals reduced the number of susceptible CD4+ cells
(lymphocytes and macrophages) that became initially
infected in these animals as compared to the controls,
thus allowing the cell-mediated responses to more effec-
tively control infection. Studies are currently underway to
evaluate this possibility. Indeed, our studies indicate that
CD8+ cell-antiviral responses are involved in the long-
term control of SHIVSF162P4 replication in previously
vaccinated animals, as it was previously recorded in
SHIVDH12-, SIVmac251-, or SIVmac239-infected naı¨ve
macaques (Jin et al., 1999; Matano et al., 1998; Schmitz
et al., 1999a). Our results, however, indicate that the long-
term control of SHIVSF162P4 infection is not solely due to
the presence of cellular-mediated antiviral responses, but
also to the antiviral effect of the anti-HIV envelope
antibodies. We also note that in addition to CD8+ T
lymphocytes with lytic or suppressive activities, NK cells
that also express the CD8 antigen, and which were also
eliminated upon cM-T807-administration, may participate
in the long-term control of SHIVSF162P4 infection.
In summary, our studies suggest that even if a vaccina-
tion methodology is not effective in eliciting high enough
titers of neutralizing antibodies to offer sterilizing immunity
against HIV, an efficient priming of neutralizing antibody
responses by vaccination will offer a significant benefit to a
vaccinee that eventually becomes infected, by allowing its
immune system to more rapidly and more effectively control
viral replication. Therefore, vaccination methodologies
against HIV should aim at priming both B and T cell
responses that are as broad as possible.Materials and methods
Vaccines and vaccination methodology
A detailed description of the vaccination methodology,
as well as the generation and production of the various
immunogens, was reported earlier (Barnett et al., 2001;
Srivastava et al., 2003). Briefly, rhesus macaques of
Indian origin received three monthly intradermal and
intramuscular immunizations with a DNA vector (2 mg
total) expressing the gp140 envelope form derived from
the HIV-1 SF162 (SF162gp140) or SF162DV2
(DV2gp140) viruses (Stamatatos et al., 2000). SF162DV2
V2 was derived from SF162 by deleting the central 30
amino acids of the V2 loop (Stamatatos and Cheng-
Mayer, 1998). In the current study, the gp120–gp41
cleavage site was eliminated from the DV2gp140 protein
expressed during the DNA phase of immunization (Sri-
vastava et al., 2003). In our previous study, the gp120–
gp41 cleavage site was present on the DV2gp140 immu-
nogen (Cherpelis et al., 2001b). In both studies, the
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had an intact gp120–gp41 cleavage site. The DNA-
encoded HIV envelope sequences were codon-optimized.
Ten months later, the animals were immunized a fourth
time with DNA and at the same time with the
corresponding recombinant gp140 proteins (0.1 mg of
protein administered intramuscularly) produced in CHO
cells, purified as trimers and adjuvanted in MF-59C
(Chiron Co., Emeryville, CA). One of the control animals
discussed here, animal M844, received three administra-
tions of the ‘‘empty’’ DNA vector and the MF-59C
adjuvant (mock immunization).
Determination of CD3+, CD4+, and CD8+ T lymphocyte
numbers in the periphery and lymph nodes
Absolute CD3+, CD4+, and CD8+ T lymphocyte numb-
ers were measured on a Coulter Epics XL.MCL Flow-
cytometer using anti-CD3-FITC (clone SP34, BD, San
Diego, CA), anti-CD4-PE (clone M-T477, BD, San Diego,
CA), and anti-CD8-PC5 (clone B9.11, Immunotech, Beck-
man Coulter, Marseille, France). Appropriate anti-mouse Ig
isotypes were used as negative controls.
Antibody responses
Binding antibodies
Titers were determined throughout the immunization
protocol and following viral challenge as previously de-
scribed (Barnett et al., 2001). Briefly, purified soluble olig-
omeric DV2gp140 or SF162gp140 proteins (500 ng/ml in
100 mM NaHCO3, pH 8.5) were adsorbed onto Immulon
2HB 96 well plates (ThermoLabsystems, Franklin, MA) (0.1
ml per well) by an overnight incubation at room temperature.
Non-adsorbed protein molecules were removed by washing
with TBS (25 mM Tris/144 mM NaCl, pH 7.6) and the wells
were blocked with SuperBlock (SB) (Pierce, Rockford, IL)
according to the manufacturer’s instructions. Serially diluted
(in SB with 0.05% Tween-20) heat-inactivated (56 jC for 35
min) sera were added to the wells (0.1 ml per well) for 1 h at
37 jC. Pre-immunization sera were used as negative controls.
Unbound antibodies were removed by TBS-washing and the
HIVenvelope-bound antibodies were detected with the use of
a goat-anti-human IgG coupled to alkaline phosphatase
(Zymed Immunochemicals, South San Francisco, CA)
(1:30000 dilution in SB and 0.05%Tween 20) (1 h incubation
at 37 jC). The wells were washed with TBS, and substrate for
alkaline phosphatase (DAKOCytomation, Carpinteria, CA)
was added (50 Al per well) for 1 h at room temperature. Upon
addition of an equal amount of Amplifier (DAKOCytoma-
tion), the OD490nm signals were recorded from each well on
a Vmax microplate reader (Molecular Devises, Sunnyvale,
CA). A plot of the OD490nm signals versus serum dilution
was generated, and end-point antibody titers were determined
as the highest post-immunization (or post-viral challenge)
serum dilution that produces an OD490nm signal 3 times thatof the OD490nm produced by the pre-immunization sera at
their lowest dilution.
Neutralizing antibodies
Neutralization assays were performed using human
PBMC that was activated for 3 days with PHA (Sigma,
St. Louis, MO, 3 Ag/ml) as target cells, as we previously
described (Barnett et al., 2001). SHIVSF162P4 (100 TCID50
in 50 Al of complete RPMI media containing 40 U/ml of IL-
2 [Hoffmann-La Roche]) was pre-incubated in triplicate
with an equal volume of serially diluted heat-inactivated
pre-immunization, post-immunization, or post-challenge
sera for 1 h at 37 jC, in 96-well U-bottom plates (Becton
Dickinson, Franklin Lakes, NJ). Pre-immunization sera
served as controls for nonspecific neutralization. To each
well, 0.1 ml of complete media containing 0.4  106 PHA-
activated human PBMC was added. Following a 24-h incu-
bation at 37 jC, half the volume of each well was replaced
with complete RPMI media. Following centrifugation of the
plates (5 min at 2000 rpm), half the volume of each well was
again replaced with fresh media. The concentration p27
antigen in the supernatant of SHIVSF162P4-infected cultures
was determined with a commercially available kit (Zepto-
Metrix Corporation, Buffalo, NY). The percent inhibition of
infection at a given dilution of sera collected post-vaccina-
tion or post-infection was calculated taking into account the
nonspecific neutralization recorded with sera collected be-
fore the initiation of immunization (Barnett et al., 2001).
CD8+ cell depletion
During acute infection
The immunized animals were infused with the anti-CD8
MAb OKT8F before their exposure to virus, as previously
described (Cherpelis et al., 2001b). Briefly, the animals
received three daily intravenous administrations of OKT8F
(2 mg/kg of body weight). Control animals M844 and C640
were similarly treated with an isotype control MAb OKT3,
which does not bind to macaque CD3. CD8 depletion was
evaluated using the anti-CD8 MAb OKTA-FITC that rec-
ognizes a different epitope than that recognized by OKT8F
(data not shown).
During chronic infection
Depletion of CD8+ cells during the chronic phase of
SHIVSF162P4 infection was achieved by infusing the anti-
CD8 MAb, cM-T807, as previously reported (Schmitz et al.,
1999a). Briefly, at day 0 of treatment, cM-T807 was
administered subcutaneously (10 mg/kg of body weight).
Three and five days later, the animals were intravenously
infused with cM-T807 (5 mg/kg of body weight).
SHIVSF162P4 challenge
Seven weeks following the end of the immunization and
1 day following the last administration of the anti-CD8
C. Buckner et al. / Virology 320 (2004) 167–180178antibody OKT8F (or of the OKT3 MAb in the case of the
controls), the animals were challenged by an intravenous
administration of 100 TCID50 of a cell-free stock of the
SHIVSF162P4 virus (Harouse et al., 1999).
Viral load measurements
The SIV bDNA assay (Bayer Reference Testing Labo-
ratory, Emeryville, CA) was employed to quantify plasma
SIV RNA copy numbers. The lower quantitation limit of
this assay is 500 SIV RNA copies per milliliter.
IFN-c ELISPOT
Cryopreserved PBMC was thawed, enumerated, and
plated at a density of 2  105 live cells per well of a 96-
well flat-bottomed plate that were previously coated with an
anti-IFN-g antibody (Ucytech # CT 126). Peptides (15-mers
with an 11 amino acid overlap) derived from the homolo-
gous SIVmac239 Gag (125 total peptides, spanning the
entire protein) or the related SHIVSF162P3 Env (211 total
peptides, spanning the entire protein) were obtained from
the NIAID, Reference and Reagent Program. Peptides were
dissolved in DMSO. Two HIV Env peptide pools were
prepared by mixing equal amounts of each of the first 106
and last 105 Env-derived peptides. Two SIV Gag peptides
pools were prepared by mixing equal amounts of each of the
first 63 and last 62 Gag-derived peptides. Pooled peptides
were aliquoted and kept frozen (20 jC) until further use.
Pooled peptides were added (10 Al) into the wells (total
volume of 0.1 ml) containing PBMC, at a final concentra-
tion of 1 Ag/ml for each individual peptide. As a positive
control, PBMC were incubated with Staphylococcus En-
terotoxin B (SEB) (5 or 0.5 Ag/ml). As negative control,
PBMC were plated in medium alone (containing the same
concentration of DMSO [0.6–1% v/v] present in the wells
incubated with peptides). The cells were incubated for 24
h at 37 jC and processed according to manufacturer’s
specifications using the Monkey IFN-g ELISPOT Kit (U-
CyTech bv Ucytech University, Utrecht, The Netherlands).
The number of IFN-g secreting cells in each well was
determined using a Bioreader 3000 (BioSys Inc., Mont-
gomery Village, MD). Only wells containing ELISPOT
counts of twice the background (PBMC incubated in cell
medium with DMSO) were considered significant. The
results are reported as the sum of the responses recorded
with the two Env or Gag peptide pools.Acknowledgments
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